Featured Research

from universities, journals, and other organizations

TB Vaccine Enters New Clinical Trials

Date:
May 1, 2009
Source:
University of Oxford
Summary:
The world's leading candidate for a tuberculosis vaccine is to enter Phase IIb proof-of-concept clinical trials, making it the first TB candidate vaccine for more than 80 years to get to this advanced stage of clinical trials in infants.

A Gambian infant is inoculated as part of a previous MRC study with the MVA85A vaccine.
Credit: Image courtesy of University of Oxford

The world’s leading candidate for a tuberculosis vaccine, developed at the University of Oxford, is to enter Phase IIb proof-of-concept clinical trials, making it the first TB candidate vaccine for more than 80 years to get to this advanced stage of clinical trials in infants.

More than two billion people are infected with tuberculosis (TB) – approximately one out of every three people on the planet – and 1.8 million die annually from the disease.

Oxford researchers have developed a promising new vaccine against TB. The Oxford-Emergent Tuberculosis Consortium Ltd, a joint venture between the University of Oxford and Emergent BioSolutions Inc, is taking the vaccine forward.

The announcement of the next phase of trials was made April 23 by the Aeras Global TB Vaccine Foundation, the Oxford-Emergent Tuberculosis Consortium Ltd, Isis Innovation, the Wellcome Trust and the University of Cape Town (UCT). The study will be conducted in South Africa, around 100 km from Cape Town, by the South African Tuberculosis Vaccine Initiative (SATVI) of UCT.

A new vaccine is urgently needed, as BCG is currently the only available vaccine against TB, and provides only variable protection against pulmonary tuberculosis, which accounts for most of the worldwide disease burden.

The trial will enroll 2,784 children less than one year of age, all of whom have received BCG at birth. It is expected that the trial will generate important safety, immunogenicity and preliminary efficacy data about the vaccine candidate.

The Aeras Global TB Vaccine Foundation is working with the Consortium to develop the vaccine, called MVA85A/AERAS-485, with additional funding from the Wellcome Trust. The vaccine candidate was originally developed at the University of Oxford by Dr Helen McShane, a Wellcome Trust Senior Clinical Research Fellow, working with Dr Sarah Gilbert, a Reader in Vaccinology, and Professor Adrian Hill, a Wellcome Trust Principal Research Fellow. It was licensed by Isis Innovation, the University’s technology transfer company to the Oxford-Emergent Tuberculosis Consortium in July 2008. The vaccine has been awarded orphan drug status by the European Medicines Agency (EMEA) and is the most clinically advanced of a new generation of tuberculosis vaccine candidates.

‘We believe this is the most exciting advance in the field of TB vaccines for over 80 years,’ said Dr Helen McShane of the Jenner Institute, University of Oxford, ‘and it is a testament to the commitment shown by the partners and funders involved. We have shown that this vaccine is safe and stimulates strong immune responses. This trial will hopefully show that the vaccine can protect people from getting TB and enable the global community to begin to control this devastating disease.’

'The search for a new TB vaccine is a complex and challenging process requiring a broad commitment and we are pleased to be collaborating with so many dedicated and talented researchers on this important effort,’ said Jerald C Sadoff, MD, President & CEO of the Aeras Global TB Vaccine Foundation. ‘There is still a long road ahead, but this marks an important milestone toward the goal of a more effective TB vaccine.’

The Aeras Global TB Vaccine Foundation is a non-profit organization working as a Product Development Partnership to develop new tuberculosis vaccines and ensure that they are distributed to all who need them around the world. Aeras collaborates with academia, industry, foundations and governments to develop new TB vaccine candidates and delivery systems, manufacture vaccines at low cost and establish intellectual property rights to assure their future availability and affordability. Aeras is funded by the Bill & Melinda Gates Foundation, the Netherlands Ministry of Foreign Affairs, the Danish International Development Agency, the Research Council of Norway and the U.S. Centers for Disease Control and Prevention.

The Oxford-Emergent Tuberculosis Consortium Ltd is a joint venture between the University of Oxford and Emergent Product Development UK Ltd. The Consortium was formed with the aim of developing the MVA85A TB vaccine to meet both developed and developing country health needs.


Story Source:

The above story is based on materials provided by University of Oxford. Note: Materials may be edited for content and length.


Cite This Page:

University of Oxford. "TB Vaccine Enters New Clinical Trials." ScienceDaily. ScienceDaily, 1 May 2009. <www.sciencedaily.com/releases/2009/04/090423205902.htm>.
University of Oxford. (2009, May 1). TB Vaccine Enters New Clinical Trials. ScienceDaily. Retrieved September 23, 2014 from www.sciencedaily.com/releases/2009/04/090423205902.htm
University of Oxford. "TB Vaccine Enters New Clinical Trials." ScienceDaily. www.sciencedaily.com/releases/2009/04/090423205902.htm (accessed September 23, 2014).

Share This



More Health & Medicine News

Tuesday, September 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Liberia Pleads for Help to Fight Ebola

Liberia Pleads for Help to Fight Ebola

AP (Sep. 22, 2014) Liberia's finance minister is urging the international community to quickly follow through on pledges of cash to battle Ebola. Bodies are piling up in the capital Monrovia as the nation awaits more help. (Sept. 22) Video provided by AP
Powered by NewsLook.com
Ebola Doctor Says Border Controls Critical

Ebola Doctor Says Border Controls Critical

AP (Sep. 22, 2014) A Florida doctor who helped fight the expanding Ebola outbreak in West Africa says the disease can be stopped, but only if nations quickly step up their response and make border control a priority. (Sept. 22) Video provided by AP
Powered by NewsLook.com
Global Ebola Aid Increasing But Critics Say It's Late

Global Ebola Aid Increasing But Critics Say It's Late

Newsy (Sep. 21, 2014) More than 100 tons of medical supplies were sent to West Africa on Saturday, but aid workers say the global response is still sluggish. Video provided by Newsy
Powered by NewsLook.com
Sierra Leone in Lockdown to Control Ebola

Sierra Leone in Lockdown to Control Ebola

AP (Sep. 21, 2014) Sierra Leone residents remained in lockdown on Saturday as part of a massive effort to confine millions of people to their homes in a bid to stem the biggest Ebola outbreak in history. (Sept. 20) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins